Targeted treatment for glioblastoma using a new drug approach
Official title: Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
Funded at Wake Forest University Health Sciences · NIH-11001446 · Data updated 2026-11-12
This study is testing a new treatment for glioblastoma, a tough type of brain cancer, using a special method to deliver targeted medicine directly to the tumor while protecting healthy brain tissue, and it has shown encouraging results in dogs with similar tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | December 9, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $603,422 |
| NIH project number | 5R01CA276233-03 |
| Project ID | NIH-11001446 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of brain tumors or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research focuses on developing a novel immunotherapy for glioblastoma (GBM), a challenging brain cancer. It utilizes a combination of targeted cytotoxins delivered through a specialized method called convection-enhanced delivery, which aims to directly attack tumor cells while minimizing damage to surrounding healthy tissue. The approach is based on the overexpression of specific receptors in GBM cells, allowing for precise targeting. Previous trials in dogs with similar tumors have shown promising results, including significant tumor reduction and improved survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with glioblastoma.
How similar studies have gone: This approach has shown success in preliminary trials with canine patients, indicating potential for effectiveness in human cases.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Debinski, Waldemar — Wake Forest University Health Sciences
- Study coordinator: Debinski, Waldemar
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.